[What is proven in the treatment of systemic lupus erythematosus?]

Was ist gesichert in der Therapie des systemischen Lupus erythematodes?

Publisher: Springer Country of Publication: Germany NLM ID: 0414162 Publication Model: Print Cited Medium: Internet ISSN: 1435-1250 (Electronic) Linking ISSN: 03401855 NLM ISO Abbreviation: Z Rheumatol Subsets: MEDLINE

Publication: 2006- : Heidelberg : Springer
Original Publication: Darmstadt, Steinkopff.

Lupus Erythematosus, Systemic*/therapy ; Immunosuppressive Agents*/therapeutic use ; Evidence-Based Medicine*; Humans ; Treatment Outcome ; Exercise Therapy ; Hydroxychloroquine/therapeutic use ; Combined Modality Therapy ; Antirheumatic Agents/therapeutic use ; Glucocorticoids/therapeutic use

Systemic lupus erythematosus (SLE) is an autoimmune disease with variable clinical presentation and organ involvement. Early diagnosis and rapid achievement of low disease activity or remission reduces organ damage and improves prognosis. Therapeutic principles can be divided into so-called basic measures and immunosuppressive treatment. Novel drugs have been developed in recent years, with new classes of agents being added for the treatment of SLE. These include biologic therapies and approved therapeutic options for the treatment of lupus nephritis. In light of improved treatment options, good disease control can now frequently be achieved; with savings on glucocorticoids, combination therapies are increasingly being used. Of great importance is the consistent use of basic measures, which include the use of hydroxychloroquine, optimization of cardiovascular risk factors, UV protection, bone-protective measures, and the implementation of vaccinations. In the treatment of lupus nephritis, conservative therapeutic measures for nephroprotection play a crucial role in renal prognosis. Finally, non-pharmacological therapy options such as exercise therapy are of great importance for improving quality of life.
(© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)

Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS (2010) Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 39(4):257–268. (PMID: 10.1016/j.semarthrit.2008.10.00719136143)
Moe SR, Haukeland H, Brunborg C, Botea A, Damjanic N, Wivestad GÅ, Øvreås H, Bøe T, Orre A, Garen T, Lilleby V, Provan SA, Molberg Ø, Lerang K (2023) Persisting mortality gap in systemic lupus erythematosus; a population-based study on juvenile- and adult-onset SLE in Norway 1999–2022. Rheumatology 28:kead519 (Sep).
Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C (2020) Lupus nephritis. Nat Rev Dis Primers 6(1):7. (PMID: 10.1038/s41572-019-0141-931974366)
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78(9):1151–1159. (PMID: 10.1136/annrheumdis-2018-21481931383717)
Gladman DD, Ibañez D, Urowitz MB (2000) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291.
Yee CS, Farewell V, Isenberg DA, Rahman A, Teh LS, Griffiths B, Bruce IN, Ahmad Y, Prabu A, Akil M, McHugh N, D’Cruz D, Khamashta MA, Maddison P, Gordon C (2004) British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 56(12):4113–4119. https://doi.org/10.1002/art.23130. (PMID: 10.1002/art.23130)
Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, Wahono CS, Chen SL, Jin O, Morton S, Hoi A, Huq M, Nikpour M, Morand EF (2016) Asia-pacific lupus collaboration. Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis 75(9):1615–1621. (PMID: 10.1136/annrheumdis-2015-20772626458737)
van Vollenhoven RF, Bertsias G, Doria A, Isenberg D, Morand E, Petri MA, Pons-Estel BA, Rahman A, Ugarte-Gil MF, Voskuyl A, Arnaud L, Bruce IN, Cervera R, Costedoat-Chalumeau N, Gordon C, Houssiau FA, Mosca M, Schneider M, Ward MM, Alarcon G, Aringer M, Askenase A, Bae SC, Bootsma H, Boumpas DT, Brunner H, Clarke AE, Coney C, Czirják L, Dörner T, Faria R, Fischer R, Fritsch-Stork R, Inanc M, Jacobsen S, Jayne D, Kuhn A, van Leeuw B, Limper M, Mariette X, Navarra S, Nikpour M, Olesinska MH, Pons-Estel G, Romero-Diaz J, Rubio B, Schoenfeld Y, Bonfá E, Smolen J, Teng YKO, Tincani A, Tsang-A-Sjoe M, Vasconcelos C, Voss A, Werth VP, Zakharhova E, Aranow C (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 8(1):e538. (PMID: 10.1136/lupus-2021-000538348193888614136)
Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas DT (2023) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. https://doi.org/10.1136/ard-2023-224762. (PMID: 10.1136/ard-2023-22476237094880)
Aringer M, Schneider M (2016) Management des systemischen Lupus erythematodes [Management of systemic lupus erythematosus]. Internist 57(11):1052–1059. (PMID: 10.1007/s00108-016-0135-627670650)
Parodis I, Girard-Guyonvarc’h C, Arnaud L, Distler O, Domján A, Van den Ende CHM, Fligelstone K, Kocher A, Larosa M, Lau M, Mitropoulos A, Ndosi M, Poole JL, Redmond A, Ritschl V, Alexanderson H, Sjöberg Y, von Perner G, Uhlig T, Varju C, Vriezekolk JE, Welin E, Westhovens R, Stamm TA, Boström C (2023) EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis. Ann Rheum Dis. https://doi.org/10.1136/ard-2023-224416. (PMID: 10.1136/ard-2023-224416)
Liang H, Tian X, Cao LY, Chen YY, Wang CM (2014) Effect of psychological intervention on health-related quality of life in people with systemic lupus erythematosus: a systematic review. Int J Nurs Sci 1(3):298–305.
da Hora TC, Lima K, Maciel RRBT (2019) The effect of therapies on the quality of life of patients with systemic lupus erythematosus: a meta-analysis of randomized trials. Adv Rheumatol 59(1):34. (PMID: 10.1186/s42358-019-0074-831358064)
Parisis D, Bernier C, Chasset F, Arnaud L (2019) Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev 18(11):102393. (PMID: 10.1016/j.autrev.2019.10239331520802)
Canadian Hydroxychloroquine Study Group (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324(3):150–154. (PMID: 10.1056/NEJM199101173240303)
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69(1):20–28. (PMID: 10.1136/ard.2008.10176619103632)
Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA, ALMS Group (2010) Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 62(1):211–221. (PMID: 10.1002/art.2505220039429)
Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Mitjavila F, Castro SA, Cuquet Pedragosa J, Ortiz-Santamaria V, Plana MM, Cortés-Hernández J (2017) Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis 76(9):1575–1582. (PMID: 10.1136/annrheumdis-2016-21088228450313)
Aringer M, Fischer-Betz R, Hiepe F, Kommission Pharmakotherapie der DGRh Germany Society of Rheumatology (2013) Stellungnahme zum Einsatz von Mycophenolat-Mofetil beim systemischen Lupus erythematodes [Statement on the use of mycophenolate mofetil for systemic lupus erythematosus]. Z Rheumatol 72(6):575–580. (PMID: 10.1007/s00393-013-1213-y23756593)
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721–731. (PMID: 10.1016/S0140-6736(10)61354-221296403)
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918–3930. (PMID: 10.1002/art.30613221277085007058)
Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383(12):1117–1128. (PMID: 10.1056/NEJMoa200118032937045)
Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R, TULIP‑2 Trial Investigators (2020) Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med 382(3):211–221. (PMID: 10.1056/NEJMoa191219631851795)
Kalunian KC, Furie R, Morand EF, Bruce IN, Manzi S, Tanaka Y, Winthrop K, Hupka I, Zhang LJ, Werther S, Abreu G, Hultquist M, Tummala R, Lindholm C, Al-Mossawi H (2023) A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol. 75(2):253–265. https://doi.org/10.1002/art.42392. (PMID: 10.1002/art.4239236369793)
Morand EF, Furie RA, Bruce IN, Vital EM, Dall’Era M, Maho E, Pineda L, Tummala R (2022) Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatol. 4(4):e282–e292. https://doi.org/10.1016/S2665-9913(21)00317-9. (PMID: 10.1016/S2665-9913)
Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group (2024) KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 105(1S):S1–S69. https://doi.org/10.1016/j.kint.2023.09.002. (PMID: 10.1016/j.kint.2023.09.002)
Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397(10289):2070–2080. (PMID: 10.1016/S0140-6736(21)00578-X33971155)
Saxena A, Ginzler EM, Gibson K, Satirapoj B, Santillán AEZ, Levchenko O, Navarra S, Atsumi T, Yasuda S, Chavez-Perez NN, Arriens C, Parikh SV, Caster DJ, Birardi V, Randhawa S, Lisk L, Huizinga RB, Teng YKO (2023) Safety and efficacy of long-term Voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial. Arthritis Rheumatol. https://doi.org/10.1002/art.42657. (PMID: 10.1002/art.4265737466424)
Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50(12):3934–3940. (PMID: 10.1002/art.2066615593207)
Carneiro JR, Sato EI (1999) Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 26(6):1275–1279. (PMID: 10381042)
Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G, LUNAR Investigator Group (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64(4):1215–1226. https://doi.org/10.1002/art.34359. (PMID: 10.1002/art.3435922231479)
Alshaiki F, Obaid E, Almuallim A, Taha R, El-Haddad H, Almoallim H (2018) Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol 5(2):118–126. https://doi.org/10.5152/eurjrheum.2018.17096. (PMID: 10.5152/eurjrheum.2018.17096301853616072690)
Crisafulli F, Andreoli L, Zucchi D, Reggia R, Gerardi MC, Lini D, Tani C, Zatti S, Franceschini F, Mosca M, Tincani A (2023) Variations of C3 and C4 before and during pregnancy in systemic lupus erythematosus: association with disease flares and obstetric outcomes. J Rheumatol 50(10):1296–1301. (PMID: 10.3899/jrheum.2022-113537127323)
Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, Doria A, Fischer-Betz R, Forger F, Moraes-Fontes MF, Khamashta M, King J, Lojacono A, Marchiori F, Meroni PL, Mosca M, Motta M, Ostensen M, Pamfil C, Raio L, Schneider M, Svenungsson E, Tektonidou M, Yavuz S, Boumpas D, Tincani A (2017) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76(3):476–485. (PMID: 10.1136/annrheumdis-2016-20977027457513)

Keywords: Biological therapy; Glucocorticoids; Hydroxychloroquine; Lupus nephritis; Systemic lupus erythematosus/basic treatment measures
Local Abstract: [Publisher, German] Der systemische Lupus erythematodes (SLE) ist eine Autoimmunerkrankung mit variabler klinischer Präsentation und Organbeteiligung. Eine frühzeitige Diagnose sowie das zügige Erreichen einer niedrigen Krankheitsaktivität oder Remission reduzieren Organschäden und verbessern die Prognose. Die Behandlungsansätze lassen sich unterteilen in sogenannte Basismaßnahmen und die immunsuppressiven Therapien. Die medikamentösen Therapieoptionen wurden in den letzten Jahren grundlegend erweitert, dabei sind neue Wirkstoffklassen für die Therapie des SLE hinzugekommen. Dies schließt Biologikatherapien und zugelassene Therapieoptionen für die Behandlung der Lupusnephritis ein. Aufgrund verbesserter Behandlungsmöglichkeiten kann unter Einsparung von Glukokortikoiden häufig eine gute Krankheitskontrolle erreicht werden, dabei kommen zunehmend Kombinationstherapien zum Einsatz. Von großer Wichtigkeit ist der konsequente Einsatz der Basismaßnahmen, hierzu zählen der Einsatz von Hydroxychloroquin, die Optimierung der kardiovaskulären Risikofaktoren, ein Schutz vor ultravioletter Strahlung, knochenprotektive Maßnahmen und die Durchführung der Schutzimpfungen. In der Behandlung der Lupusnephritis spielen konservative Therapiemaßnahmen zur Nephroprotektion eine entscheidende Rolle für die renale Prognose. Hinsichtlich einer Verbesserung der Lebensqualität haben auch nichtpharmakologische Therapieoptionen wie die Bewegungstherapie eine große Bedeutung.

0 (Immunosuppressive Agents)
4QWG6N8QKH (Hydroxychloroquine)
0 (Antirheumatic Agents)
0 (Glucocorticoids)

Date Created: 20240722 Date Completed: 20240813 Latest Revision: 20240813

20240813

10.1007/s00393-024-01551-6

39037548